Clinical Trials

37 enrolled

Triple Negative Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

33 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05192798 2025-02-27

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

128 enrolled

Triple Negative Breast Neoplasms

NCT06786026 2025-02-06

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

60 enrolled

Triple Negative Breast Neoplasms

NCT04408118 2024-06-04

ATRACTIB

100 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04739670 2024-03-01

BELLA

Phase 2 Unknown

31 enrolled

Recurrence, Triple Negative Breast Neoplasms

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT04395989 2023-12-22

FUTURE-SUPER

Phase 2 Unknown

139 enrolled

Triple Negative Breast Neoplasms

NCT06125080 2023-11-09

UTILIZABLE

78 enrolled

Triple Negative Breast Neoplasms

NCT05303038 2022-06-09

Castle06(BC)

Phase 2 Unknown

15 enrolled

Triple Negative Breast Neoplasms

NCT03577743 2021-03-09

Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

54 enrolled

Triple Negative Breast Neoplasms

NCT00733408 2018-12-04

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

59 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00479674 2015-02-18

ABC

41 enrolled 8 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01208480 2012-04-10

Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer

45 enrolled